96 results on '"Perol, M."'
Search Results
2. Efficacité du Pembrolizumab en première ligne chez les patients avec cancer du poumon non à petites cellules, non épidermoïdes, métastatiques, PDL1 > 50 % avec mutation KRAS G12C (étude ESCKEYP–GFPC 05–2018)
3. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
4. PL02.05 IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab
5. Exploratory analyses of surrogate endpoints in metastatic non-small cell lung cancer
6. VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data
7. 186TiP An open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)
8. MA11.03 Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01
9. OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
10. FP14.05 LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).
11. Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer
12. Perceptions et connaissances sur le cancer du poumon en France : une enquête en regards croisés auprès du grand public et des médecins
13. Efficacité et tolérance de l’immunothérapie par anti-PD1/PDL1 dans le CBNPC métastatique avec mutation BRAF, HER2 ou MET, amplification MET ou translocation RET. GFPC 01-2018
14. MA21.07 Circulating Tumor DNA Analysis Depicts Potential Mechanisms of Resistance to BRAF-Targeted Therapies in BRAF+ Non-Small Cell Lung Cancer
15. MA07.05 Immune Checkpoint Inhibitor (ICPi) Re-Challenge: Outcomes Analysis in a French National Cohort of Non-Small-Cell Lung Cancer (NSCLC) Patients
16. P1.01-116 Early Immune-Related Adverse Events Under PD-1/PD-L1 Inhibitors Predict Better Progression-Free Survival in NSCLC
17. Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort
18. Crossed looks on lung cancer perception and knowledge from general public and physicians in France: Results of a two-fold survey
19. P1.01-124 Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs Crizotinib in NSCLC (ALTA-1L)
20. Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC
21. Circulating tumour DNA (ctDNA) analysis depicts mechanisms of resistance and tumour response to BRAF inhibitors in BRAF-mutant non-small cell lung cancer (NSCLC)
22. P1.04-30 Pioneer Study: Precision Immuno-Oncology for Advanced Non-Small Cell Lung Cancer Patients with PD1/L1 ICI Resistance
23. Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study
24. ES01.04 Immunotherapy, Radiotherapy and Chemotherapy Combination: A Potential New Standard?
25. Efficacité et tolérance des inhibiteurs des immuno-checkpoints (anti-PD-1/PD-L1) chez les patients atteint de CBNPC avec mutation EFGR, ALK/ROS : étude IMAD GFPC 03-2016
26. Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSé program
27. Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort
28. EVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients
29. Clinical outcomes in patients with advanced NSCLC treated with targeted therapies, with actionable mutations identified by InVisionFirst ctDNA assay
30. 138PD_PR Patient-reported outcomes (PROs) in ALEX: A phase III study of alectinib (ALEC) vs crizotinib (CRIZ) in non-small-cell lung cancer (NSCLC)
31. Activité de l’osimertinib dans les méningites carcinomateuses des cancers non à petites cellules (CPNPC) avec mutation activatrice de l’EGFR ayant déjà bénéficié d’un traitement par inhibiteur tyrosine-kinase (TKI) de l’EGFR
32. Prévalence et facteurs de risque d’aspergillose pulmonaire en oncologie thoracique : étude rétrospective sur 5
33. Étude de phase III évaluant dans le cancer bronchique non à petites cellules de stade IV et d’histologie non épidermoïde ; deux stratégies de maintenance, l’une par pémétrexed en maintenance de continuation, l’autre en fonction de la réponse à la chimiothérapie d’induction : essai IFCT-GFPC 11-01
34. Cost-Effectiveness Analysis of Afatinib Versus Gefitinib in Egfr-Mutated Population with Advanced Non-Small-Cell Lung Cancer in France
35. Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study
36. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC)
37. Pathologie pulmonaire infiltrative diffuse survenant chez des patients traités par les inhibiteurs des points de contrôle immunitaire (immunothérapie)
38. Données en « vraie vie » de patients traités par gefitinib pour un cancer bronchique non à petites cellules localement avancé ou métastatique, avec mutation de l’EGFR : résultats de l’étude EPIDAURE
39. French real-life efficacy of 1st line gefitinib in EGFR mutation-positive NSCLC in the prospective EPIDAURE study: Results by EGFR exon 19 Del and L858R mutation subtypes
40. A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC)
41. 168P: Real life practice of gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC) depending on epidermal growth factor receptor (EGFR) mutation status: Results from the prospective EPIDAURE study
42. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC – IFCT 02-01
43. Cost of Questionnaire-Based Process to Identify Occupational Exposures Among Patients with Lung Cancer
44. Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology
45. 3105 Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial
46. 3062 Ceritinib following crizotinib in ALK-positive (+) advanced NSCLC patients (pts): Results from the French Temporary Authorization for Use (ATU) experience
47. 3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy
48. Actinomycose bronchique pseudo-tumorale simulant une ré-évolution d’un cancer bronchique 14ans après la prise en charge thérapeutique initiale : à propos d’un cas
49. Évaluation d’une fiche d’aide à la décision en cas d’aggravation d’un patient cancéreux
50. Randomised, Multicentre, Phase Iii, Open-Label Study of Alectinib Vs Crizotinib in Treatment-Naïve Anaplastic Lymphoma Kinase (Alk)-Positive Advanced Nsclc (Alex Study)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.